EP3297702A4 - METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AGING - Google Patents

METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AGING Download PDF

Info

Publication number
EP3297702A4
EP3297702A4 EP16797159.7A EP16797159A EP3297702A4 EP 3297702 A4 EP3297702 A4 EP 3297702A4 EP 16797159 A EP16797159 A EP 16797159A EP 3297702 A4 EP3297702 A4 EP 3297702A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
treating aging
associated impairments
impairments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16797159.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3297702A2 (en
Inventor
Anton Wyss-Coray
Saul A. VILLEDA
Karoly Nikolich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Us Government Represented By Department Of V
University of California
Leland Stanford Junior University
Alkahest Inc
Original Assignee
U S Government Represented By Department Of Veteran Affairs
University of California
Leland Stanford Junior University
US Department of Veterans Affairs VA
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S Government Represented By Department Of Veteran Affairs, University of California, Leland Stanford Junior University, US Department of Veterans Affairs VA, Alkahest Inc filed Critical U S Government Represented By Department Of Veteran Affairs
Priority to EP21162695.7A priority Critical patent/EP3892315A1/en
Publication of EP3297702A2 publication Critical patent/EP3297702A2/en
Publication of EP3297702A4 publication Critical patent/EP3297702A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/07—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
EP16797159.7A 2015-05-18 2016-05-17 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AGING Withdrawn EP3297702A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21162695.7A EP3892315A1 (en) 2015-05-18 2016-05-17 Methods and compositions for treating aging-associated impairments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562163222P 2015-05-18 2015-05-18
PCT/US2016/032907 WO2016187217A2 (en) 2015-05-18 2016-05-17 Methods and compositions for treating aging-associated impairments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21162695.7A Division EP3892315A1 (en) 2015-05-18 2016-05-17 Methods and compositions for treating aging-associated impairments

Publications (2)

Publication Number Publication Date
EP3297702A2 EP3297702A2 (en) 2018-03-28
EP3297702A4 true EP3297702A4 (en) 2019-01-16

Family

ID=57320543

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16797159.7A Withdrawn EP3297702A4 (en) 2015-05-18 2016-05-17 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AGING
EP21162695.7A Pending EP3892315A1 (en) 2015-05-18 2016-05-17 Methods and compositions for treating aging-associated impairments

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP21162695.7A Pending EP3892315A1 (en) 2015-05-18 2016-05-17 Methods and compositions for treating aging-associated impairments

Country Status (11)

Country Link
EP (2) EP3297702A4 (ru)
JP (2) JP7134089B2 (ru)
KR (1) KR20180030965A (ru)
CN (2) CN116687969A (ru)
AU (4) AU2016265948B2 (ru)
CA (1) CA2984645C (ru)
EA (2) EA202091057A3 (ru)
HK (1) HK1248153A1 (ru)
IL (1) IL255319B2 (ru)
NZ (1) NZ738184A (ru)
WO (1) WO2016187217A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CN106163530A (zh) 2013-12-09 2016-11-23 小利兰·斯坦福大学托管委员会 用于治疗衰老相关病症的方法和组合物
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
US10617744B2 (en) 2015-06-15 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
CN108884053B (zh) * 2015-12-15 2022-01-04 斯坦福大学托管董事会 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法
WO2017189919A2 (en) 2016-04-28 2017-11-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
EP4299129A3 (en) 2017-04-26 2024-03-20 Alkahest, Inc. Dosing regimen for treatment of cognitive impairments with blood plasma products
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
IL282227B1 (en) 2018-10-26 2024-04-01 Alkahest Inc Use of plasma and plasma fractions to improve pain, wound healing and recovery after surgery
CN113081079B (zh) * 2021-03-30 2022-04-22 中国科学院生态环境研究中心 血桥限位器

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020143283A1 (en) * 1997-07-30 2002-10-03 Andrew Braverman Material for removing beta-2 microglobulin from blood
WO2011094535A2 (en) * 2010-01-28 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687751T2 (de) * 1985-09-19 1993-05-27 Toray Industries Kolonne zum entfernen von beta-2-mikroglobulin.
EP0319862B1 (de) 1987-12-11 1994-01-12 Akzo Nobel N.V. Biocompatible Dialysemembran aus Cellulose mit erhöhter Beta-2-Microglobulinadsorption
FR2646607B1 (fr) 1989-05-03 1991-08-30 Inst Nat Sante Rech Med Anticorps monoclonaux anti-b2 microglobuline
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
FR2685346B1 (fr) 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
US5240614A (en) 1992-01-10 1993-08-31 Baxter International Inc. Process for removing unwanted materials from fluids and for producing biological products
AU7623194A (en) 1993-09-03 1995-03-22 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
AU706417B2 (en) 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
FR2722411B1 (fr) 1994-07-18 1996-10-04 Union Pharma Scient Appl Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv
US5780296A (en) 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
JPH11503914A (ja) 1995-04-21 1999-04-06 セル ジェネシス，インコーポレイテッド 大ゲノムｄｎａ欠失の生成
US5776744A (en) 1995-06-07 1998-07-07 Yale University Methods and compositions for effecting homologous recombination
US5925544A (en) 1996-11-18 1999-07-20 Novo Nordisk A/S Method of homologous recombination followed by in vivo selection of DNA amplification
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US20020159995A1 (en) 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
AUPR748501A0 (en) 2001-09-04 2001-09-27 Life Therapeutics Limited Renal dialysis
US7066900B2 (en) 1998-12-23 2006-06-27 Life Therapeutics Removal of metabolic components from blood
AUPP790898A0 (en) 1998-12-23 1999-01-28 Life Therapeutics Limited Renal dialysis
JP2003506111A (ja) 1999-01-22 2003-02-18 ザ ダウ ケミカル カンパニー 血液適合性コーティングを有する表面改質ジビニルベンゼン樹脂
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
AU2002312329A1 (en) 2001-06-05 2002-12-16 The Regents Of The University Of California Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
ES2386775T3 (es) 2001-07-23 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos
US20030180811A1 (en) 2002-03-11 2003-09-25 Montero-Julian Felix A. Immunoassays for beta2-microglobulin
AU2003221886A1 (en) 2002-04-12 2003-10-27 The Board Of Trustees Of The University Of Arkansas Beta2-MICROGLOBILIN (Beta2m) AND ANTI-Beta2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS
US7037276B2 (en) 2002-07-02 2006-05-02 Precision Medical Devices, Inc. Biopsy device
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
CA2506798C (en) 2002-11-22 2013-01-22 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
WO2006130949A1 (en) 2005-06-08 2006-12-14 Replicor Inc. Anti amyloid-related disease molecules and their uses
US8211310B2 (en) 2006-11-20 2012-07-03 Cytosorbents, Inc. Size-selective polymer system
CN101888863B (zh) * 2007-12-06 2012-11-28 旭化成医疗株式会社 血液处理用多孔中空纤维膜
US20110142848A1 (en) 2008-08-07 2011-06-16 Chung Leland W K Anti-beta-2-microglobulin agents and the use thereof
WO2010040029A1 (en) 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
US8754034B2 (en) 2009-02-06 2014-06-17 The Regents Of The University Of California Structure-based design of peptide inhibitors of amyloid fibrillation
US20130331327A1 (en) 2012-06-08 2013-12-12 Vittorio Bellotti Variant Beta2-microglobulin, characterization of the same and applications thereof
EP2781523A1 (en) * 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs
US11885816B2 (en) * 2013-11-26 2024-01-30 University Of North Texas Health Science Center At Forth Worth Personalized medicine approach for treating cognitive loss

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020143283A1 (en) * 1997-07-30 2002-10-03 Andrew Braverman Material for removing beta-2 microglobulin from blood
WO2011094535A2 (en) * 2010-01-28 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A NIEZGODA ET AL: "The effect of cladribine treatment on beta-2 microglobin in the cerebrospinal fluid and serum of patients with multiple sclerosis", NEUROL NEUROCHIR POL. 2000 MAR-APR;34(2, 1 March 2000 (2000-03-01), pages 281 - 287, XP055531915, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/10962721> [retrieved on 20181210] *
S. GIORGETTI ET AL: "2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity", NEPHROLOGY DIALYSIS TRANSPLANTATION., vol. 24, no. 4, 1 January 2009 (2009-01-01), GB, pages 1176 - 1181, XP055532705, ISSN: 0931-0509, DOI: 10.1093/ndt/gfn623 *

Also Published As

Publication number Publication date
EA202091057A3 (ru) 2021-03-31
EP3892315A1 (en) 2021-10-13
EA201792437A1 (ru) 2018-04-30
JP7134089B2 (ja) 2022-09-09
AU2016265948A1 (en) 2018-01-04
EA035799B1 (ru) 2020-08-12
AU2020210181B2 (en) 2022-05-26
EP3297702A2 (en) 2018-03-28
WO2016187217A3 (en) 2017-01-05
JP2018518530A (ja) 2018-07-12
HK1248153A1 (zh) 2018-10-12
NZ738184A (en) 2019-09-27
AU2020210181A1 (en) 2020-08-13
AU2019201337B9 (en) 2020-05-21
WO2016187217A2 (en) 2016-11-24
CA2984645A1 (en) 2016-11-24
CN116687969A (zh) 2023-09-05
IL255319A0 (en) 2017-12-31
CN107921188A (zh) 2018-04-17
IL255319B2 (en) 2023-03-01
AU2019201337A1 (en) 2019-03-21
CA2984645C (en) 2023-01-10
IL255319B (en) 2022-11-01
JP2021073264A (ja) 2021-05-13
AU2022221494A1 (en) 2022-09-29
JP7323561B2 (ja) 2023-08-08
AU2019201337B2 (en) 2020-05-14
KR20180030965A (ko) 2018-03-27
EA202091057A2 (ru) 2020-12-30
AU2016265948B2 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
HK1248153A1 (zh) 用於治療衰老相關的損傷的方法和組合物
EP3328363A4 (en) COMPOSITIONS AND METHODS OF IMMUNOMODULATION
EP3379935A4 (en) METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
IL278004A (en) Methods and preparations for treating conditions related to aging
EP3380101A4 (en) EIF4-A INHIBITOR COMPOUNDS AND ASSOCIATED METHODS
EP3500289A4 (en) METHODS OF TREATING TRACHEOBRONCHOMALACIA
IL269787B (en) Methods and preparations for treating defects related to aging in CCR-3 inhibitor inventions
EP3302379A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM
EP3079708A4 (en) Methods and compositions for treating aging-associated conditions
EP3380622A4 (en) METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
EP3209298A4 (en) Compositions and methods for treating insomnia
EP3442543A4 (en) COMPOSITIONS AND METHODS FOR NEUROGENESIS
EP3352800A4 (en) PROCESS AND COMPOSITIONS FOR REDUCING METASTASES
EP3125908A4 (en) Compositions and methods for treating kidney disorders
EP3096757A4 (en) Apilimod compositions and methods for using same
ZA201707896B (en) Compositions and methods for reducing visual loss
EP3261644A4 (en) Compositions and methods for treating retinal degradation
EP3253389A4 (en) Apilimod compositions and methods for using same
EP3484515A4 (en) METHOD FOR TREATING FIBROSE
EP3148564A4 (en) Methods and compositions for immunomodulation
EP3194027A4 (en) Methods and compositions for treating psychotic disorders
EP3313387A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3314499A4 (en) TEMPORARY METHODENTIAL PRIVILEGING
EP3169684A4 (en) Methods and compositions for treating hiv-related disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20171123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Owner name: ALKAHEST, INC.

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALKAHEST, INC.

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

A4 Supplementary search report drawn up and despatched

Effective date: 20181219

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20181213BHEP

Ipc: A61M 1/36 20060101AFI20181213BHEP

Ipc: C12N 15/113 20100101ALI20181213BHEP

Ipc: A61K 31/7088 20060101ALI20181213BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Owner name: ALKAHEST, INC.

Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V

17Q First examination report despatched

Effective date: 20200203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20210316